Cancer Risk Associated with Insulin Glargine among Adult Type 2 Diabetes Patients – A Nationwide Cohort Study

Diabetes and Cancer: A Consensus Report

(2010) E. Giovannucci et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Diabetes therapy and cancer risk: causal effects and other plausible explanations

(2010) S. Hernández-Díaz et al.   DIABETOLOGIA

Diabetes Mellitus Type 2 – An Independent Risk Factor for Cancer?

(2010) V. Grote et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Insulin analogues and cancer risk: cause for concern orcause célèbre?

(2010) M. Pollak et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

A basic study design for expedited safety signal evaluation based on electronic healthcare data

(2010) Sebastian Schneeweiss   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells

(2009) Doron Weinstein et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Combined randomised controlled trial experience of malignancies in studies using insulin glargine

(2009) P. D. Home et al.   DIABETOLOGIA

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study

(2009) J. Rosenstock et al.   DIABETOLOGIA

Does diabetes therapy influence the risk of cancer?

(2009) U. Smith et al.   DIABETOLOGIA

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

(2009) J. M. Jonasson et al.   DIABETOLOGIA

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

(2009) H. M. Colhoun et al.   DIABETOLOGIA

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

(2009) C. J. Currie et al.   DIABETOLOGIA

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

(2009) L. G. Hemkens et al.   DIABETOLOGIA

Insulin glargine and malignancy: an unwarranted alarm

(2009) Stuart J Pocock et al.   LANCET

Proliferation of Colo-357 Pancreatic Carcinoma Cells and Survival of Patients With Pancreatic Carcinoma Are Not Altered by Insulin Glargine

(2008) S. Erbel et al.   DIABETES CARE